Explore more
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...
Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In ...
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback